Background. Even small delays in the treatment of breast cancer are a frequently expressed concern of patients. Knowledge about this subject is important for clinicians to counsel patients appropriately and realistically, while also optimizing care. Although data and quality measures regarding time to chemotherapy and radiotherapy have been present for some time, data regarding surgical care are more recent and no standard exists. This review was written to discuss our current knowledge about the relationship of treatment times to outcomes. Methods. The published medical literature addressing delays and optimal times to treatment was reviewed in the context of our current time-dependent standards for chemotherapy and radiotherapy. The surgical literature and the lack of a time-dependent surgical standard also were discussed, suggesting a possible standard. Results. Risk factors for delay are numerous, and tumor doubling times are both difficult to determine and unhelpful to assess the impact of longer treatment times on outcomes. Evaluation components also have a time cost and are inextricable from the patient's workup. Although the published literature has lack of uniformity, optimal times to each modality are strongly suggested by emerging data, supporting the current quality measures. Times to surgery, chemotherapy, and radiotherapy all have a measurable impact on outcomes, including disease-free survival, disease-specific survival, and overall survival. Conclusions. Delays have less of an impact than often thought but have a measurable impact on outcomes. Optimal times from diagnosis are \ 90 days for surgery, \ 120 days for chemotherapy, and, where chemotherapy is administered, \ 365 days for radiotherapy.
As the most frequent malignancy in women, breast cancer evokes widespread fear and anxiety. 1 Concern about the effect of treatment delay on breast cancer outcomes has been present for more than a century, even elaborated by Halsted in his 1907 mastectomy series where he stated, ''We no longer need the proof which our figures so unmistakably give that the slightest delay is dangerous.…'' 2 Although fear of breast cancer itself can cause delays, patients frequently inquire from their physicians about how soon they should begin treatment, concerned that undue delay will impair their likelihood of survival. 3 In breast cancer, this perception of longer times equating to poorer outcomes may be magnified by the mantra associated with mammography, that ''early detection saves lives,'' as the obverse tenet would be that late diagnosis kills patients. This perception is widespread, as illustrated by breast cancer claims where the majority of breast cancer lawsuits are based on alleged delay in diagnosis, rather than therapeutic malpractice. 4, 5 There also is no medical definition of a standard interval to diagnosis or treatment, although published studies often used specific thresholds to investigate when times become detrimental. [6] [7] [8] [9] [10] As longer times to treatment probably have a gradual and continuous effect on outcomes, series that evaluate progressive time intervals rather than a specific cutoff may capture the effect on survival more realistically. [11] [12] [13] In evaluating studies, it is important to scrutinize the defined beginning and end points of the interval in question; i.e., does the interval start at first symptom, presentation, imaging, diagnosis, or treatment and does it end with a particular component of evaluation, treatment, recurrence, or death. Scrutiny of this issue has increased, and breast cancer quality measures now exist, specifying appropriate treatment intervals, even though it remains currently unproven whether these specific measures enhance quality or survival.
BIOLOGY OF DELAY
In theory, cellular division and tumor growth should provide the most accurate method by which to assess the impact of delays on breast cancer outcomes. Tumor doubling time, which is the time required for cells to divide, should help to determine the harm caused by a longer interval. Unfortunately, tumor doubling times are not constant, likely complicating reliable prediction. Tumors initially have a parabolic exponential growth rate, but limits in blood supply, physical space, and nutrition, along with a tumor's chaotic growth pattern, cause them to exhibit Gompertzian kinetics where their rapid rate of expansion at the outset begins to decline and plateau. 15, 16 Unfortunately, tumor doubling times vary tremendously within and between studies (Table 1) , which may be, in part, due to these nonlinear growth kinetics. These investigations use a variety of methods, including review of breast imaging, metastasis development, historical assessment, and local recurrences. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Such studies estimate tumor doubling times to be between 2 and 7051 days, with medians varied from 45-260 days. 20, 25, 26 These disparate estimates suggest that we are very poor at accurately measuring these intervals and that doubling time estimations are unhelpful in determining the effect of delays on breast cancer survival. This is supported by the fact that prognostic factors, such as age, race, tumor size, grade, and lymph node metastases, have not been consistently found to correlate with tumor doubling time. 18, [23] [24] [25] [26] The total life span of a tumor cannot be accurately determined, further clouding the relationship of tumor doubling times to delays and outcomes. Cancers begin at inception when the first cell has undergone malignant transformation. The cell doubles approximately 20-30 times to reach 1 mm 3 -1 cm 3 when it becomes potentially clinically evident. This time period is referred to as the tumor's silent interval, because it is too small to allow detection. 20 The time between potential and actual diagnosis or between diagnosis and treatment are the time intervals that we typically scrutinize and try to minimize.
Although we usually measure survival from diagnosis or treatment until death, the time that a patient is at risk for metastatic disease and death from cancer begins at inception and continues through the majority of that tumor's lifespan, which occurs before it is of sufficient size to detect. Thus, delays that occur after reaching a detectable size are thought to represent only a small fraction of the time that a tumor has been in existence, posing risk to the patient. This is, in part, why 8% of women currently present with metastatic disease at diagnosis and likely the reason that most studies find that effects of a longer interval, when significant, are relatively small. 28 
SURGERY
At the time of this writing, there is no time-dependent surgery standard to specify how soon a patient should undergo operative intervention after diagnosis. This may be The time to surgery also is related to both necessary and desired components of preoperative evaluation and these are inextricable from it. For instance, preoperative MRI use adds 6.4 days to the preoperative interval, while fine needle aspirations add 6 days, and core needle and excisional biopsies add 12.7 and 17.4 days respectively. 29 Even the ideal paradigm of a preoperative multidisciplinary evaluation by medical oncology, radiation oncology, and surgery adds 12.6 days between diagnosis and surgery or 6.8 days if these are condensed into 1 day. 31 Treatment choices have an effect on the time to treatment, and many are scheduling related; lengthier procedures take longer to book into open operative time, while coordination with plastic surgery or nuclear medicine also may delay scheduling. In the United States, the use of radionuclide for sentinel node biopsy adds 2.3 days, while adding reconstruction to mastectomy increases the time to operation by 12.2 days. 29 The effect of delays on survival has been controversial. Nodal status as a surrogate for outcome has been investigated, and a modeling study in pregnant patients found that delaying treatment from 1 to 3 to 6 months was associated with an increased risk of axillary lymph node metastases, although this was based on two assumed tumor doubling times and not validated in vivo. 32 Meanwhile, a series of 818 clinically node-negative breast cancers diagnosed from [2003] [2004] [2005] [2006] , found that time to surgery was not associated with lymph node status. 33 A series that reviewed 5283 women who presented in 1988-1999 found that a delay of C 2 months in diagnosis was not associated with nodal metastases or their breast conservation rate.
Studies that evaluated the effect of timing of first treatment on outcome are shown in Table 2 and utilize varied cutoffs with results that are not uniform. One large study utilizing NCDB data found that outcomes declined only after a threshold of [ 12 weeks between diagnosis and surgery. Meanwhile a study evaluating both Surveillance Epidemiology End Results (SEER)-Medicare and NCDB data found that disease-specific survival declined by a relative 26% per month, while overall survival dropped 9-10% per month in each database, resulting in a 3.1-4.6% absolute decline with delays of 90 days. 12 This study also found that [ 98% of patients in the United States have surgery within 90 days of diagnosis in both datasets, which suggests that this may be a reasonable candidate for a time-dependent surgical threshold if one were to be defined.
CHEMOTHERAPY
We currently have a quality measure that specifies that chemotherapy should be administered within 120 days of diagnosis in women\ 70 having AJCC T1c, Stage II or III, hormone-receptor negative breast cancer. Although two standard chemotherapy regimens were established in trials that specified administration 2-4 weeks after surgery for cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) and 2-5 weeks afterwards for doxorubicin and cytoxan (AC), 35 the time from diagnosis was not specified. 34 There is unfortunately no published data evaluating whether a chemotherapy standard is better focused on time from diagnosis or surgery.
Current paradigm specifies that chemotherapy be given before radiotherapy and not delayed until afterwards, in part because of data showing that local recurrence is higher when chemotherapy is given before radiotherapy, while metastases increase when radiotherapy is given first. 36 Studies most frequently assess times from surgery to chemotherapy in 4-week intervals (Table 3) . [37] [38] [39] [40] [41] Results of these studies vary, with some finding declines in diseasefree, disease-specific, and overall survival, although an impairment from longer intervals is not always found. [36] [37] [38] [39] [40] [41] [42] [43] Delays in chemotherapy after surgery also have been explored by phenotype. In receptor-positive tumors, two studies have shown no relationship. 44, 45 A third study found that luminal A tumors are not affected but luminal B tumors have a hazard ratio of 1.93 for intervals [ 8 weeks. 46 In a recently presented abstract, among 273,521 receptor-positive patients, each additional month lowered outcome by 11.1%. 47 In the sole study evaluating receptor-negative tumors, times [ 6 weeks had a significant impact, while three studies evaluating triple negative tumors have all noted an impact on disease-specific or overall survival. [44] [45] [46] [47] One study of 4698 patients found that delay-related declines were worse for triple-negative tumors, suggesting neoadjuvant therapy be considered routinely, whereas another found in 36,505 such patients no difference in the decline between triple-negative and other phenotypes. 47 Finally, in HER2-positive tumors, one study found no impact on diseasespecific survival, while two noted that overall survival was affected by times to treatment. 44, 46, 47 
RADIOTHERAPY
Times between surgery and radiotherapy have been increasing in some countries, where longer intervals exist than in the United States. [48] [49] [50] When chemotherapy is administered, the relationship between radiation delays and survival is unclear. For instance, in a series of 482 patients with stage I or II breast cancer, an analysis adjusting for chemotherapy administration found that increasing time to radiotherapy was not associated with a local recurrence increase. 51 Such nonsignificant results may have been due to a lack of statistical power, systemic therapy mitigating the effect of delay, or timing issues surrounding chemotherapy administration confounding the analysis.
Much of the published literature evaluates timing when only surgery and radiotherapy are administered, making it easier to conceptually assess the impact of delay by eliminating the confounding of that intervening chemotherapy, although such results may not be applicable to patients receiving systemic therapy. Currently, we only have one time-dependent radiotherapy standard covering patients whether they receive chemotherapy or not. This specifies that radiotherapy be initiated within 365 days of diagnosis in patients \ 70 having breast conservation. 14 A series evaluating the SEER-Medicare dataset found that among 18,050 women [ 65, diagnosed with Stages 0-II breast cancer, having breast conservation and radiotherapy, but no chemotherapy, median time from surgery to radiation was 34 days, with one-third starting after 6 weeks. 52 An interval to radiotherapy [ 6 weeks was associated with an adjusted hazard ratio of 1.19 (95% confidence interval [CI] 1.01-1.39, p = 0.004) for local recurrence, with a 0.5% increase in the local recurrence risk per day.
Meanwhile, an older single-institution series reviewed 653 node-negative Stage I and II patients not receiving systemic therapy, dividing them between those starting radiotherapy \ 4, 5-8, and 9-12 weeks postoperatively. 53 The last group was the smallest, and while no compromise in outcomes \ 8 weeks was demonstrable, failure rates in the longest group also ''did not suggest a greater risk of…recurrence for this group,'' although 5-year recurrence hormone receptor positive *Times are between last breast surgery until radiotherapy for the radiotherapy-first group, and until chemotherapy in the chemotherapy-first group **Chemotherapy received by 47% within 1 month, 37% between months 1-2, 6% between months 2-3, and 10% after 3 rates for the three groups would now be considered high at 24, 21, and 15% respectively. 53 In contrast, a series evaluating the SEER-Medicare database divided 13,907 Stage I-II women having breast conservation who did not receive chemotherapy after their last surgery and found that radiation C 12 weeks (3 months) had worse disease-specific and overall survival with hazard ratios of 3.81 (95% CI 2.98-4.87, p \ 0.0001) and 1.91 (95% CI 1.63-2.23, p \ 0.0001), respectively, when adjusting for demographics and tumor factors. 54 A more recent study of 568 T1/2, node-negative patients treated with breast conservation therapy without systemic therapy found that after 11.2 years of follow-up, no differences in disease-free survival were found up to 16 weeks with no definitive conclusion possible [ 16 , and a drop in overall survival by an absolute 3.1-4.6%, this threshold seems appropriate, because it allows 1 month to begin chemotherapy by the current quality measure. The 365-day quality measure for radiotherapy allows for sufficient time to undergo chemotherapy regimens of varying lengths, while allowing a short time to begin simulation and planning (a). When chemotherapy is not administered, however, the radiotherapy standard provides an excess of time, even when using 20 weeks postoperative, which is the longest interval found to not confer a survival decline (b). This suggests that a second standard, measured from time of surgery when chemotherapy is not administered, might optimize care. Dx diagnosis; OS overall survival; Sim simulation; hypoFx hypofractionation; WBXRT whole breast radiotherapy; TC taxotere and cyclophosphamide; DDAC dose-dense doxorubicin and cyclophosphamide; ?T paclitaxel; CMF cyclophosphamide, methotrexate, and 5-fluorouracil
Finally, other series have found that longer times to radiotherapy are of no consequence, up to a point. A study of 1962 women in British Columbia with T1-3 breast cancer who did not receive chemotherapy found that intervals of 0-20 weeks did not impair disease-free survival. 56 Another study with overlapping authors using the same dataset, subsequently evaluating 6428 women with T1-2, N0 breast cancers treated with breast conservation but no chemotherapy, found no differences in any outcome up to 20 weeks, although there was a decline thereafter. 57 Meanwhile, a study analyzing data from three International Breast Cancer Study Group trials also found no effect of up to 20 weeks in 964 patients having breast conservation surgery, radiotherapy, and adjuvant endocrine therapy. 58 Although the literature is varied, outcomes appear to remain unchanged after surgery when times to radiotherapy are at least 8 weeks and likely up to 20 weeks in the absence of chemotherapy with longer times remaining safe when chemotherapy is given in the interim (Table 4) .
Although the current standard, allowing a full year (365 days) from diagnosis seems lengthy, this allows time for systemic therapy. With 98% of surgeries performed within 90 days, and chemotherapy initiated \ 120 days according to that time-dependent standard, this allows 84 days and 140 days for our modern-day shortest and longest chemotherapy regimens of TC x 4 and dose dense AC x 4 and T x 12, respectively. If no pauses occur in these regimens, these would complete on days 204 and 260, respectively. For patients even requiring 6 months of CMF, chemotherapy would end on day 288. This would allow only 2-4 weeks to begin simulation and planning, which takes 4-6 weeks, to begin radiotherapy by that 365 day threshold (Fig. 1a) . In a setting where patients do not get chemotherapy, a 365-day interval to radiation is not only unnecessary but may actually lower survival, even if we consider the 20-week threshold found by the three studies above (Fig. 1b) .
CONCLUSIONS
In short, times to surgery, chemotherapy, and radiotherapy have an impact on outcomes. While there is no time-dependent surgical standard, time from diagnosis to surgery (in the nonneoadjuvant setting) of [ 90 days, which occurs in \ 2% of patients in the United States, lowers overall survival by 3.1-4.6%, and would be a reasonable time-dependent standard if one were to be set. Times to chemotherapy as set by the current standard of \ 120 days from diagnosis would allow for that interval, while limiting any effect of chemotherapy delay. Meanwhile, times to radiotherapy of \ 365 days in patients receiving chemotherapy, as defined by the current standard, allow appropriate time for systemic therapy, although patients not receiving chemotherapy should likely have radiation far earlier, beginning no more than 20 weeks from surgery where feasible.
